UP!

PCYC $261.16

PCYC target price
261.16
0
0
Pharmacyclics LLC
Type
Subsidiary of AbbVie
Traded as Formerly NASDAQ: PCYC
Industry Biopharmaceutical
Founded 1991; 26 years ago (1991)
Founders Jonathan Sessler, Richard A. Miller
Headquarters Sunnyvale, California
Area served
Worldwide
Key people
Robert Duggan, former CEO and Chairman
Parent AbbVie
Website pharmacyclics.com

Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. Its primary focus is upon the development of "novel therapies for the treatment of cancer and immune-mediated diseases." In 2017, Xynomic Pharmaceuticals acquired all global rights to abexinostat from Pharmacyclics.

In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire oncology firm Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. The merger is expected to close in mid-2015.

Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."

As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2015-05-29 Reiterated Rating BTIG Research Neutral
2015-04-20 Reiterated Rating BMO Capital Markets Positive
2015-03-06 Reiterated Rating Credit Suisse Neutral
2015-03-06 Downgrade Leerink Swann Outperform to Market Perform
2015-03-06 Boost Price Target WallachBeth Capital Hold $222.00 to $261.00
2015-03-06 Reiterated Rating Credit Suisse Group AG Neutral
2015-03-05 Set Price Target Piper Jaffray Hold $184.00
2015-03-05 Downgrade Nomura Buy to Neutral $196.00 to $261.25
2015-03-05 Downgrade Wells Fargo & Co. Outperform to Market Perform $261.25
2015-03-05 Downgrade BTIG Research Buy to Neutral
2015-03-05 Boost Price Target RBC Capital Sector Perform $145.00 to $261.00
2015-03-05 Downgrade Wells Fargo Outperform to Market Perform $261.25
2015-03-05 Set Price Target Piper Jaffray Cos. Hold $184.00
2015-03-05 Downgrade Nomura Holdings Inc. Buy to Neutral $196.00 to $261.25
2015-03-05 Boost Price Target Royal Bank Of Canada Sector Perform $145.00 to $261.00
2015-03-03 Downgrade Wedbush Outperform to Neutral $225.00 to $234.00
2015-03-02 Boost Price Target Leerink Swann Outperform to Outperform $204.00 to $240.00
2015-02-27 Downgrade Goldman Sachs Hold $184.00
2015-02-27 Downgrade Credit Suisse Hold $233.00
2015-02-27 Downgrade Goldman Sachs Group Inc. Hold $184.00
2015-02-26 Downgrade Goldman Sachs Buy to Neutral $217.82 to $184.00
2015-02-26 Boost Price Target Robert W. Baird $240.00
2015-02-26 Downgrade Credit Suisse Outperform to Neutral $163.00 to $223.00
2015-02-26 Downgrade WallachBeth Capital Buy to Hold $228.00
2015-02-25 Downgrade Deutsche Bank Buy to Hold $235.00
2015-02-25 Downgrade Deutsche Bank AG Buy to Hold $235.00
2015-02-19 Reiterated Rating Stifel Nicolaus Hold
2015-02-19 Boost Price Target Deutsche Bank Buy $180.00 to $205.00
2015-02-19 Boost Price Target Leerink Swann Outperform $153.00 to $204.00
2015-02-19 Downgrade JPMorgan Chase & Co. Overweight to Neutral $152.00 to $173.00
2015-02-19 Upgrade Nomura Neutral to Buy $195.00 to $196.00
2015-02-19 Downgrade Roth Capital Buy to Neutral $189.00 to $187.00
2015-01-29 Boost Price Target Roth Capital Buy $188.00 to $189.00
2015-01-14 Set Price Target Roth Capital Buy $188.00
2015-01-14 Boost Price Target Citigroup Inc. Buy $145.00 to $155.00
2015-01-13 Set Price Target Robert W. Baird Buy $173.00
2015-01-13 Set Price Target RBC Capital Hold $130.00
2015-01-06 Initiated Coverage BTIG Research Buy $225.00
2015-01-05 Set Price Target Roth Capital Buy $188.00
2015-01-05 Downgrade Nomura Buy to Neutral $175.00 to $158.00
2014-11-05 Reiterated Rating JMP Securities Market Outperform $200.00 to $204.00
2014-11-05 Reiterated Rating Nomura Buy $158.00 to $175.00
2014-11-05 Reiterated Rating Morgan Stanley Equal Weight $103.00 to $111.00
2014-10-27 Reiterated Rating Nomura Buy $158.00
2014-10-17 Reiterated ROTH Capital Buy $185 to $188
2014-10-15 Initiated Coverage Citigroup Inc. Buy $145.00
2014-10-14 Boost Price Target Roth Capital Buy $183.00 to $185.00
2014-09-16 Boost Price Target William Blair $186.00
2014-09-11 Reiterated Rating Morgan Stanley Equal Weight $101.00
2014-09-04 Initiated Coverage SunTrust Neutral $140.00
2014-09-04 Initiated Coverage SunTrust Banks Inc. Neutral $140.00
2014-08-05 Boost Price Target William Blair Outperform $150.00 to $180.00
2014-08-01 Upgrade WallachBeth Hold to Buy
2014-08-01 Reiterated Rating Deutsche Bank Buy $180.00
2014-08-01 Reiterated Rating JPMorgan Chase & Co. Overweight $150.00 to $152.00
2014-08-01 Boost Price Target RBC Capital $95.00 to $100.00
2014-08-01 Reiterated Rating Nomura Buy $174.00 to $177.00
2014-08-01 Boost Price Target Morgan Stanley $94.00 to $101.00
2014-08-01 Boost Price Target JMP Securities Market Outperform $191.00 to $200.00
2014-08-01 Boost Price Target Credit Suisse $121.00 to $163.00
2014-08-01 Upgrade WallachBeth Capital Hold to Buy $160.00
2014-07-29 Upgrade Leerink Swann Market Perform to Outperform $102.00 to $142.00
2014-07-28 Reiterated Rating Roth Capital Buy
2014-07-14 Lower Price Target Nomura $177.00 to $174.00
2014-06-30 Reiterated Rating Credit Suisse Outperform $121.00
2014-05-27 Downgrade RBC Capital Outperform to Sector Perform $110.00 to $95.00
2014-05-27 Lower Price Target Morgan Stanley Equal Weight $100.00 to $95.00
2014-05-05 Lower Price Target Nomura $186.00 to $177.00
2014-05-05 Lower Price Target RBC Capital Outperform $150.00 to $110.00
2014-05-05 Lower Price Target Morgan Stanley Equal Weight $120.00 to $100.00
2014-05-02 Downgrade Piper Jaffray Overweight to Neutral
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-03-26 Initiated Coverage Morgan Stanley Equal Weight $120.00
2014-02-24 Boost Price Target Roth Capital $183.00
2014-02-21 Boost Price Target Deutsche Bank Buy $170.00 to $180.00
2014-02-21 Set Price Target JMP Securities $163.00 to $191.00
2014-02-21 Boost Price Target Nomura $166.00
2014-02-21 Boost Price Target Robert W. Baird $163.00 to $173.00
2014-02-13 Boost Price Target Roth Capital $166.00
2014-01-08 Initiated Coverage Nomura Buy
2013-12-18 Initiated WallachBeth Hold $108
2013-12-18 Initiated Coverage WallachBeth Capital Hold $108.00
2013-12-03 Boost Price Target RBC Capital $125.00 to $150.00
2013-11-26 Initiated Coverage Piper Jaffray Overweight $160.00
2013-11-14 Boost Price Target Roth Capital Buy $144.00 to $151.00
2013-11-14 Boost Price Target JMP Securities Market Outperform $135.00 to $163.00
2013-11-14 Reiterated Rating Wedbush Outperform $165.00
2013-11-08 Boost Price Target Robert W. Baird Outperform $123.00 to $132.00
2013-10-30 Reiterated Rating Goldman Sachs Buy $170.00
2013-10-30 Boost Price Target Roth Capital $144.00
2013-10-11 Upgrade Goldman Sachs Neutral to Buy $123.14 to $170.00
2013-10-04 Initiated Coverage Wells Fargo & Co. Outperform
2013-10-04 Initiated Coverage Wells Fargo Outperform
2013-09-26 Initiat
2013-09-26 Initiated Coverage JPMorgan Chase & Co. Overweight to Overweight $142.00 to $170.00
2013-09-26 Initiated Coverage Deutsche Bank Buy $170.00
2013-09-25 Boost Price Target JMP Securities Market Outperform $125.00 to $135.00
2013-09-23 Reiterated Rating Lazard Capital Markets Buy $141.00
2013-09-23 Initiated Coverage William Blair Outperform $143.00
2013-09-23 Boost Price Target Morgan Stanley Equal Weight $94.00 to $103.00
2013-09-18 Boost Price Target Goldman Sachs Buy $102.00 to $111.00
2012-12-12 Reiterated Wedbush Outperform $93 to $110
2012-05-17 Reiterated Rodman & Renshaw Mkt Outperform $22 to $40
2012-05-17 Reiterated Needham Buy $23 to $32
2011-12-07 Initiated Rodman & Renshaw Mkt Outperform $20
2010-06-07 Reiterated Wedbush Outperform $8 to $16
2010-04-14 Reiterated Roth Capital Buy $7 to $11
2010-02-12 Downgrade BWS Financial Buy to Hold
2015-05-29 Reiterated Rating BTIG Research Neutral
2015-04-20 Reiterated Rating BMO Capital Markets Positive
2015-03-06 Reiterated Rating Credit Suisse Neutral
2015-03-06 Downgrade Leerink Swann Outperform to Market Perform
2015-03-06 Boost Price Target WallachBeth Capital Hold $222.00 to $261.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In PCYC 3 funds of 2213 total. Show all

Fund name Ticker shares
Placemark Investments, Inc. 15250
BAIRD ROBERT W & CO INC /WI/ 920
BOSTON PRIVATE BANK & TRUST CO 100

Major Shareholders

Name Relationship Total Shares Holding stocks
Hemmi Gregory VP Chemical Operations 0.05%  (38004) PCYC /
Outten Matthew VP, Commercial Operations 0.01%  (10758) PCYC /
Sjovall Boultbee Paula S EVP, Sales and Marketing 0.01%  (9653) PCYC /
Erdtmann Rainer M Sr. VP, IR and Admin 0.01%  (5701) PCYC /